Published in Antimicrob Agents Chemother on July 01, 1998
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med (2008) 5.81
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother (2010) 2.41
Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One (2010) 1.88
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother (2012) 1.34
Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol (2006) 1.25
Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem Rev (2014) 1.13
Tenofovir resistance and resensitization. Antimicrob Agents Chemother (2003) 1.10
Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study. J Acquir Immune Defic Syndr (2012) 1.01
Prodrugs of phosphonates and phosphates: crossing the membrane barrier. Top Curr Chem (2015) 1.00
Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother (2002) 0.98
An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate. Int J Pharm (2015) 0.84
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials (2013) 0.83
Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults. AIDS Res Treat (2012) 0.82
Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis. Antimicrob Agents Chemother (2015) 0.78
Development of a Novel Formulation that Improves Pre-clinical Bioavailability of Tenofovir Disoproxil Fumarate. J Pharm Sci (2016) 0.78
Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy. J Drug Deliv Sci Technol (2009) 0.77
Amidate prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine as inhibitors of adenylate cyclase toxin from Bordetella pertussis. Antimicrob Agents Chemother (2013) 0.76
Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations. PLoS One (2017) 0.75
An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014. Acta Pharm Sin B (2015) 0.75
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science (1995) 9.48
Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother (1998) 3.01
Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet (1989) 2.54
Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother (1993) 2.52
9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother (1996) 2.15
Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. AIDS Res Hum Retroviruses (1997) 2.12
Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res (1997) 1.53
Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother (1995) 1.36
Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab Dispos (1997) 1.26
Acyclic adenine nucleoside phosphonates in plasma determined by high-performance liquid chromatography with fluorescence detection. Clin Chem (1992) 1.14
Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis (1997) 1.12
Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother (1996) 1.07
Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm Res (1994) 1.03
Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharm Res (1997) 0.90
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science (1995) 9.48
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods (1988) 7.74
(E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci U S A (1979) 5.28
A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues. J Med Chem (2001) 4.82
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med (1998) 4.77
Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis (1980) 4.67
CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci (2001) 4.12
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc (1997) 3.69
Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med (1997) 3.62
Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis (2001) 3.47
Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol (2001) 3.40
Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin derivatives with 3-amino-2-methylmercapto quinazolin-4(3H)-one. Pharm Acta Helv (1999) 3.24
Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother (1998) 3.01
A novel selective broad-spectrum anti-DNA virus agent. Nature (1986) 2.98
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A (2001) 2.96
Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1988) 2.82
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol (2001) 2.79
Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother (1993) 2.52
Angiogenesis: regulators and clinical applications. Biochem Pharmacol (2001) 2.47
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother (1998) 2.44
An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. Proc Natl Acad Sci U S A (1991) 2.37
Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med (2000) 2.33
Synthesis and antimicrobial activity of Schiff and Mannich bases of isatin and its derivatives with pyrimidine. Farmaco (1999) 2.31
Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res (1987) 2.27
Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J Virol (2000) 2.24
Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother (1987) 2.24
Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother (1998) 2.19
Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis (1995) 2.16
Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother (1988) 2.16
9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother (1996) 2.15
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS (1996) 2.14
Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. AIDS Res Hum Retroviruses (1997) 2.12
Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus. J Virol Methods (1987) 2.10
Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A (1991) 2.08
On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine. Proc Natl Acad Sci U S A (1981) 2.00
Differential affinities of 5-(2-halogenovinyl)-2'-deoxyuridines for deoxythymidine kinases of various origins. Mol Pharmacol (1981) 1.94
HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology (1993) 1.92
Synthesis and antiviral activity evaluation of some aminoadamantane derivatives. J Med Chem (1994) 1.91
Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res (1997) 1.90
Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmacol (1997) 1.89
Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem (1989) 1.89
Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr (1999) 1.88
Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate. Virology (1992) 1.87
Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. J Med Chem (2000) 1.86
Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett (1979) 1.84
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A (2000) 1.83
Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs. Pharmacol Ther (1984) 1.82
CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages. J Virol (1998) 1.81
Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol (1998) 1.81
Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo. J Virol (1968) 1.78
Synthesis of imidazo[1,2-a]pyridines as antiviral agents. J Med Chem (1998) 1.78
AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol (2001) 1.77
Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res (1998) 1.75
Cytotoxic activities of Mannich bases of chalcones and related compounds. J Med Chem (1998) 1.74
Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci U S A (1989) 1.74
Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother (1998) 1.72
Expression of human fibroblast interferon gene in Escherichia coli. Nature (1980) 1.72
Antiviral and antimetabolic activities of neplanocins. Antimicrob Agents Chemother (1985) 1.71
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS). J Med Chem (1986) 1.70
Comparative efficacy of antiherpes drugs in different cell lines. Antimicrob Agents Chemother (1982) 1.68
Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci U S A (1991) 1.67
Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun (1987) 1.67
Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg Med Chem Lett (2001) 1.64
Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob Agents Chemother (1991) 1.63
A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J Med Chem (1989) 1.62
Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J Med Virol (1993) 1.61
Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo. J Clin Invest (1999) 1.61
Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.60
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother (1988) 1.60
Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS (1998) 1.58
Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis (1996) 1.58
Bis-DEAE-fluorenone: mechanism of antiviral protection and stimulation of interferon production in the mouse. J Infect Dis (1971) 1.56
Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrob Agents Chemother (1993) 1.54
Current concepts of interferon and interferon induction. Annu Rev Med (1970) 1.53
Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res (1997) 1.53
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. J Med Chem (1987) 1.53
Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem (1998) 1.53
HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation. Proc Natl Acad Sci U S A (2000) 1.53
Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology (1990) 1.53
Anti-human immunodeficiency virus drug combination strategies. Antivir Chem Chemother (1998) 1.53
Antiviral activity of polyacrylic and polymethacrylic acids. I. Mode of action in vitro. J Virol (1968) 1.52
Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS (1998) 1.52
Polyacetal carboxylic acids: a new group of antiviral polyanions. J Virol (1970) 1.51
1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity. J Med Chem (1994) 1.50
Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis. Mol Pharmacol (1987) 1.49
Selective activity of several cholic acid derivatives against human immunodeficiency virus replication in vitro. J Acquir Immune Defic Syndr (1989) 1.49
Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res (1988) 1.47
Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Infect Dis (1983) 1.47
Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun (1989) 1.46
Synthesis, antibacterial, antifungal and anti-HIV activities of norfloxacin mannich bases. Eur J Med Chem (2000) 1.46
Failure to quantify viral load with two of the three commercial methods in a pregnant woman harboring an HIV type 1 subtype G strain. AIDS Res Hum Retroviruses (1998) 1.46